Merck Serono resurrects failed lung cancer vaccine
This article was originally published in Scrip
Executive Summary
Merck Serono is to begin a new Phase III trial of its cancer vaccine Stimuvax, which failed in a pivotal Phase III trial last year. The product, renamed tecemotide, will be studied in a subgroup in which a benefit had been seen in the previous trial.